Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 30 (8), 4496-4503
- https://doi.org/10.1007/s00330-020-06700-4
Abstract
The acquisition of adequate tumor sample is required to verify primary tumor type and specific biomarkers and to assess response to therapy. Historically, invasive surgical procedures were the standard methods to acquire tumor samples until advancements in imaging and minimally invasive equipment facilitated the paradigm shift image-guided biopsy. Image-guided biopsy has improved sampling yield and minimized risk to the patient; however, there are still limitations, such as its invasive nature and its consequent limitations to longitudinal tumor monitoring. The next paradigm shift in sampling technique will need to address these issues to provide a more reliable and less invasive technique. Recently, liquid biopsy (LB) has emerged as a non-invasive alternative to tissue sampling. This technique relies on direct sampling of blood or other bodily fluids in contact with the tumor in order to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating RNAs-in particular microRNA (miRNAs). Clinical applications of LB involve different steps of cancer patient management including screening, detection of disease recurrence, and evaluation of acquired resistance. With any paradigm shift, old techniques are often relegated to a secondary option. Although image-guided biopsies may appear as a passive spectator on the rapid advancement of LB, the two techniques may well be codependent. Interventional radiology may be integral to directly sample the liquid surrounding or draining from the tumor. In addition, LB may help to correctly select the patients for image-guided loco-regional treatments, to determine its treatment endpoint, and to early detect recurrence.Funding Information
- A.I.R.C. (IG 2018 ID. 21091; IG 2015 n. 16788; AIRC IG 2018 - ID. 21923 project)
- Roche Italia (Roche per la ricerca 2017)
- Siemens Healthineers (research grant)
- National Cancer Institute (RCA235564A)
This publication has 90 references indexed in Scilit:
- Clonal evolution in cancerNature, 2012
- MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteinsNature, 2011
- Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapseBritish Journal of Cancer, 2011
- Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor CellsClinical Cancer Research, 2010
- Exosomes: Extracellular organelles important in intercellular communicationJournal of Proteomics, 2010
- Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotypeBritish Journal of Cancer, 2010
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkersNature, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer (Retracted article. See vol. 175, pg. 192, 2023)Gynecologic Oncology, 2008